Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis

Schwaneck, Eva Christina; Renner, Regina; Junker, L.; Einsele, Hermann; Gadeholt, Ottar; Geissinger, Eva; Kleinert, Stefan; Gernert, Michael; Tony, Hans‐Peter; Schmalzing, Marc

doi:10.1002/art.40654

Cited by 26 publications

(19 citation statements)

References 35 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, the number of LGL cells was lower than the usual threshold used to define LGL leukaemia (≥500/mm 3 ) in 4/8 patients. However, LGLe represented ≥10% of total lymphocytes, a threshold recently proposed in RA 12. In fact, these four patients had a global lymphopenia (<1000/mm 3 ) due to disease activity and/or associated treatments.…”

mentioning

confidence: 78%

See 1 more Smart Citation

Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes

et al. 2019

View full text Add to dashboard Cite

mentioning

confidence: 78%

“…Surprisingly, Schwaneck et al did not identify RTX as a risk factor for LGLe in RA 12. Also, RTX has been used in the treatment of LGL leukaemia associated with RA, sometimes with success 13.…”

mentioning

confidence: 99%

Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes

et al. 2019

View full text Add to dashboard Cite

“…Thus, in one study, 3.6% of patients with RA had >10% LGL (CD3 + CD56 + ) in the PB. These patients were not clinically distinct, other than developing cytopenias, but significantly more were under anti TNFα therapy and~60% of the LGL expansions were γδ T cell clones [29]. Furthermore, among 14 patients with γδ T cell-LGL leukemia, (11 men and three women), six had a history of RA.…”

Section: Numerical Alterations Of γδ T Cells In Ramentioning

confidence: 98%

The Role of Gamma Delta T Cells in Autoimmune Rheumatic Diseases

Bank

2020

Cells

View full text Add to dashboard Cite

Autoimmune rheumatic diseases (ARDs), affecting ~1–1.5% of all humans, are associated with considerable life long morbidity and early mortality. Early studies in the 1990s showed numerical changes of the recently discovered γδ T cells in the peripheral blood and in affected tissues of patients with a variety of ARDs, kindling interest in their role in the immuno-pathogenesis of these chronic inflammatory conditions. Indeed, later studies applied rapid developments in the understanding of γδ T cell biology, including antigens recognized by γδ T cells, their developmental programs, states of activation, and cytokine production profiles, to analyze their contribution to the pathological immune response in these disorders. Here we review the published studies addressing the role of γδ T in the major autoimmune rheumatic diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, systemic lupus erythematosus and scleroderma, and animal models thereof. Due to their unique properties spanning adaptive and innate immune functions, the ever deeper understanding of this unique T cell population is shedding new light on the pathogenesis of, while potentially enabling new therapeutic approaches to, these diseases.

show abstract

“…In Einzelfällen kann zur Reduktion des Infektionsrisikos die Gabe von G-CSF (granulocyte-colony stimulating factor) erforderlich sein. In einer aktuellen Arbeit fand sich zudem bei Patienten mit RA unter längerfristiger Behandlung mit TNF-alpha-Blockern eine klonale Expansion von T-Lymphozyten (T cell large granular lymphocyte [T-LGL]) [52]. Die Bedeutung dieses Befundes für die klinische Routine bleibt aktuell noch offen.…”

Section: Hämatologische Nebenwirkungen Unter Rituximab (Anti-cd20/b-zunclassified

Seltene Nebenwirkungen von biologischen DMARD

Nigg¹,

Feuchtenberger²

2019

Arthritis und Rheuma

View full text Add to dashboard Cite

ZusammenfassungDie Einführung der Biologika Ende der 1990er-Jahre hat zweifelsohne die Behandlungsmöglichkeiten entzündlich rheumatischer Systemerkrankung nachhaltig verändert, um nicht zu sagen revolutioniert. Zusammen mit der Etablierung von Konzepten zur frühen Diagnose und therapeutischen Intervention sowie Treat-to-Target-Strategien mit dem Ziel der Remission hat sich die Prognose rheumatologischer Patienten erheblich verbessert. Nach nunmehr bis zu 20-jähriger Anwendung in der klinischen Routine kann zudem von einer überwiegend guten Verträglichkeit und Sicherheitsdatenlage der Biologika ausgegangen werden. Dennoch finden sich mitunter seltene unerwünschte Arzneimittelwirkungen. Dieser Artikel beschäftigt sich genau mit den eher selteneren unerwünschten Arzneimittelwirkungen, welche in der klinischen Routine dennoch berücksichtigt werden müssen.

show abstract

Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis

Abstract: RA patients with long-term exposure to TNF-blocking agents were at a greater risk of developing clonal expansions of LGLs. This finding may prompt clinicians to refrain from using these substances in RA patients with known T cell aberrations.

Cited by 26 publications

References 35 publications

Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes

Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes

The Role of Gamma Delta T Cells in Autoimmune Rheumatic Diseases

Seltene Nebenwirkungen von biologischen DMARD

Contact Info

Product

Resources

About